Hong Xiao

Dr. Hong Xiao

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2005 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
SFSebastien Fuchs
Sebastien Fuchs
KFKristen Frenzel
Kristen Frenzel
CHChristine Hubert
Christine Hubert
RLRobert Lyng
Robert Lyng
LMLaurent Muller
Laurent Muller
KBKenneth E Bernstein
Kenneth E Bernstein

10 December 2023 in Journal of Clinical Oncology
Verified
Journal Article
Open access
MMMarkus Moehler
Markus Moehler
HXHong Xiao
Hong Xiao
SBSteven I. Blum
Steven I. Blum
EEElena Elimova
Elena Elimova
DCDavid Cella
David Cella
LWLucjan Wyrwicz
Lucjan Wyrwicz
PURPOSE: In CheckMate 649, first-line nivolumab plus chemotherapy prolonged overall survival versus chemotherapy in patients with advanced/metastatic non–human epidermal growth factor receptor 2 (HER2)-positive gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC). We present exploratory patient-reported outcomes (PROs). METHODS: In patients (N = 1,581) concurrently randomly assigned 1:1 to nivolumab plus chemotherapy or chemotherapy and in those with tumor PD-L1 expression at a combined positive score (CPS) of ≥5, health-related quality of life (HRQoL) was assessed using the EQ-5D and Functional Assessment of Cancer Therapy-Gastric (FACT-Ga), which included the FACT-General (FACT-G) and Gastric Cancer subscale (GaCS). The FACT-G GP5 item assessed treatment-related symptom burden. Longitudinal changes in HRQoL were assessed using mixed models for repeated measures in the PRO analysis population (randomly assigned patients with baseline and ≥1 postbaseline assessments). Time to symptom or definitive deterioration analyses were also conducted. RESULTS: In the PRO analysis population (n = 1,360), PRO questionnaire completion rates were mostly >80% during treatment. Patient-reported symptom burden was not increased with nivolumab plus chemotherapy versus chemotherapy. Mean improved changes from baseline were greater with nivolumab plus chemotherapy versus chemotherapy for FACT-Ga total, GaCS, and EQ-5D visual analog scale in patients with a CPS of ≥5; results were similar for the overall PRO analysis population. In CPS ≥5 and all randomly assigned populations, nivolumab plus chemotherapy reduced the risk of symptom deterioration versus chemotherapy, on the basis of FACT-Ga total score and GaCS; time to definitive deterioration was longer, and the risk of definitive deterioration in HRQoL was reduced with nivolumab plus chemotherapy across EQ-5D and most FACT-Ga measures (hazard ratio [95% CI] <1). CONCLUSION: Compared with chemotherapy alone, first-line nivolumab plus chemotherapy showed stable or better on-treatment HRQoL in patients with advanced/metastatic non–HER2-positive GC/GEJC/EAC and also showed decreased risk of definitive HRQoL deterioration.

1 August 2015 in Applied Geography
Verified
Journal Article
Closed access
PGPierre E Goovaerts
Pierre E Goovaerts
HXHong Xiao
Hong Xiao
GAGeorges Adunlin
Georges Adunlin
AAAskal Ali
Askal Ali
FTFei Tan
Fei Tan
YHYoujie Huang
Youjie Huang

7 January 2020 in Drug Safety
Verified
Journal Article
Closed access
PDF file
MMMonica A. Muñoz
Monica A. Muñoz
GPGerald J. Dal Pan
Gerald J. Dal Pan
YWYu-Jung Jenny Wei
Yu-Jung Jenny Wei
Chris DelcherChris Delcher
Chris Delcher
HXHong Xiao
Hong Xiao
AWAlmut G. Winterstein
Almut G. Winterstein

1 April 2018 in Clinical Therapeutics
Verified
Journal Article
Closed access
XJXinyi Jiang
Xinyi Jiang
HXHong Xiao
Hong Xiao
RSRichard Segal
Richard Segal
WMWilliam Cary Mobley
William Cary Mobley
HPHaesuk Park
Haesuk Park

14 February 2024 in Drug Safety
Verified
Journal Article
Open access
PDF file
MMMonica A. Muñoz
Monica A. Muñoz
GPGerald J. Dal Pan
Gerald J. Dal Pan
YWYu-Jung Jenny Wei
Yu-Jung Jenny Wei
HXHong Xiao
Hong Xiao
Chris DelcherChris Delcher
Chris Delcher
AWAlmut G. Winterstein
Almut G. Winterstein
Introduction The Food and Drug Administration Adverse Event Reporting System (FAERS) is a vital source of new drug safety information, but whether adverse event (AE) information collected from these systems adequately captures experiences of the overall United States (US) population is unknown. Objective To examine determinants of consumer AE reporting in the USA. Methods Five-year AE reporting rate per 100,000 residents per US county were calculated, mapped, and quartiled for AE reports received directly from consumers between 2011 and 2015. Associations between county-level sociodemographic factors obtained from County Health Rankings and AE reporting rates were evaluated using negative binomial regression. Results Reporting rates were variable across US counties with > 17.6 reports versus ≤ 5.5 reports/100,000 residents in the highest and lowest reporting quartile, respectively. Controlling for drug utilization, counties with higher reporting rates had higher proportions of individuals age ≥ 65 years (e.g., 2.4% reporting increase per 1% increase in individuals age > 65, incidence rate ratio (IRR): 1.024, 95% confidence interval (CI): 1.017–1.030), higher proportions of females (IRR: 1.027, 95% CI 1.012–1.043), uninsured (IRR: 1.009, 95% CI 1.005–1.013), higher median log household incomes (IRR: 1.897, 95% CI 1.644–2.189) and more mental health providers per 100,000 residents (IRR: 1.003, 95% CI 1.001–1.004). Lower reporting was observed in counties with higher proportions of individuals age ≤ 18 years (IRR: 0.966, 95% CI 0.959–0.974), American Indian or Alaska Native individuals (IRR: 0.991, 95% CI 0.986–0.996), individuals not proficient in English (IRR: 0.978, 95% CI 0.965–0.991), and individuals residing in rural areas within a county (IRR: 0.998, 95% CI 0.997–0.998). Conclusions Observed variations in consumer AE reporting may be related to sociodemographic factors and healthcare access. Because these factors may also correspond to AE susceptibility, voluntary AE reporting systems may be suboptimal for capturing emerging drug safety concerns among more vulnerable populations.